Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts
Obesity results from disruptions in the regulation of body weight, driven by complex interactions between genetic and environmental factors. Genetic forms, such as monogenic and syndromic obesity, are rare but severe conditions often presenting with early-onset obesity, eating disorders, and a rang...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-02-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/58211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823865309215326208 |
|---|---|
| author | Agnieszka Starzyk Piotr Charzewski |
| author_facet | Agnieszka Starzyk Piotr Charzewski |
| author_sort | Agnieszka Starzyk |
| collection | DOAJ |
| description |
Obesity results from disruptions in the regulation of body weight, driven by complex interactions between genetic and environmental factors. Genetic forms, such as monogenic and syndromic obesity, are rare but severe conditions often presenting with early-onset obesity, eating disorders, and a range of comorbidities. These forms of obesity pose significant challenges to treatment and health management. While historically managed through lifestyle interventions, recent advances in targeted therapies, including GLP-1 receptor agonists, MC4R agonists, and other pharmacological options, have shown significant potential in addressing genetic and syndromic obesity. These treatments, when combined with lifestyle modifications and surgical interventions, represent a step forward in improving health outcomes and quality of life for affected individuals. The integration of genetic diagnostics into clinical practice is critical to identifying appropriate candidates for these therapies and personalizing treatment plans to address the heterogeneous nature of obesity. Continued research into the molecular mechanisms and biomarkers of obesity is essential for refining these strategies, ensuring equitable access, and ultimately reducing the global health burden of obesity.
|
| format | Article |
| id | doaj-art-cacb6687c26147dd86627c32353b22b3 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-cacb6687c26147dd86627c32353b22b32025-02-08T08:25:07ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-02-013810.12775/QS.2025.38.58211Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness EnthusiastsAgnieszka Starzyk0https://orcid.org/0009-0002-8696-4187Piotr Charzewski1https://orcid.org/0009-0007-5170-3899Medical University of WarsawAkademia Leona Koźmińskiego w Warszawie Obesity results from disruptions in the regulation of body weight, driven by complex interactions between genetic and environmental factors. Genetic forms, such as monogenic and syndromic obesity, are rare but severe conditions often presenting with early-onset obesity, eating disorders, and a range of comorbidities. These forms of obesity pose significant challenges to treatment and health management. While historically managed through lifestyle interventions, recent advances in targeted therapies, including GLP-1 receptor agonists, MC4R agonists, and other pharmacological options, have shown significant potential in addressing genetic and syndromic obesity. These treatments, when combined with lifestyle modifications and surgical interventions, represent a step forward in improving health outcomes and quality of life for affected individuals. The integration of genetic diagnostics into clinical practice is critical to identifying appropriate candidates for these therapies and personalizing treatment plans to address the heterogeneous nature of obesity. Continued research into the molecular mechanisms and biomarkers of obesity is essential for refining these strategies, ensuring equitable access, and ultimately reducing the global health burden of obesity. https://apcz.umk.pl/QS/article/view/58211obesitybody fatbiomarkersCardiovascular diseaseheart failurediabetes mellitus |
| spellingShingle | Agnieszka Starzyk Piotr Charzewski Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts Quality in Sport obesity body fat biomarkers Cardiovascular disease heart failure diabetes mellitus |
| title | Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts |
| title_full | Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts |
| title_fullStr | Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts |
| title_full_unstemmed | Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts |
| title_short | Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts |
| title_sort | understanding obesity and the role of pharmacological treatments insights for health and fitness enthusiasts |
| topic | obesity body fat biomarkers Cardiovascular disease heart failure diabetes mellitus |
| url | https://apcz.umk.pl/QS/article/view/58211 |
| work_keys_str_mv | AT agnieszkastarzyk understandingobesityandtheroleofpharmacologicaltreatmentsinsightsforhealthandfitnessenthusiasts AT piotrcharzewski understandingobesityandtheroleofpharmacologicaltreatmentsinsightsforhealthandfitnessenthusiasts |